Redx Pharma said it had recorded promising pre-clinical efficacy data for a lead fibrosis treatment compound.
New data was produced from three independent pre-clinical animal models of lung, kidney and liver fibrosis, all testing the company lead ROCK2 compound.
The data showed it was able to suppress collagen deposition and pathways associated with fibrosis, indicating that selective ROCK2 inhibition could have an impact on established fibrosis.
The data would be presented in more detail later in 2019 at a scientific meeting.
Redx said it planned to nomiate a drug candidate for the ROCK2 programme by mid 2019, following final safety evaluations.
If nominated for development, it would be developed as an orally-administered treatment, with first-in-man studies commencing in 2020.
At 9:22am: (LON:REDX) Redx Pharma Plc share price was +1.25p at 8p